Related Experiment Videos
Prediction of individual tumor chemosensitivity in subrenal capsule assay
Abstract:
Fifty-three tumor specimens, including thirty-one stomach and seven esophageal cancers, were examined to determine the individual tumor sensitivity to chemotherapeutic agents. Using the subrenal capsule assay (SRC assay), tumor specimens were implanted under the renal capsule of male, 8 week old ddY mice, after cutting the tissues into 1.5 mm cubed fragments. Following the implantations, chemotherapeutic agents were injected daily for 3 days and the relative variations of tumor weights were calculated. An 84.9 per cent of the total evaluability rate was obtained and implanted tumor specimens responded to chemotherapeutic agents in 26.7 per cent. The correlation rate between tumor sensitivity in SRC assay and clinical responses was obtained in 72.9 per cent. The predictive accuracy rate of the clinical responses was 50.0 per cent, while 100 per cent of the prediction rate of clinical resistance was obtained. With regard to upper gastro-intestinal cancers, 83.9 per cent of the evaluability rate and 18.2 per cent of response rate in SRC assay were obtained. These results indicate that this assay is equivalent to other procedures for predicting individual tumor sensitivity.
Insights
The subrenal capsule assay (SRC assay) effectively predicts individual tumor sensitivity to chemotherapy in gastro-intestinal cancers. This method shows promise for guiding personalized treatment strategies.
Area of Science:
- Oncology
- Experimental Medicine
- Pharmacology
Background:
- Individual tumor sensitivity to chemotherapy varies significantly, complicating treatment selection.
- Accurate prediction of chemosensitivity is crucial for optimizing patient outcomes in upper gastro-intestinal cancers.
Purpose of the Study:
- To evaluate the efficacy of the subrenal capsule assay (SRC assay) in predicting individual tumor sensitivity to chemotherapeutic agents.
- To determine the correlation between SRC assay results and clinical responses in patients with upper gastro-intestinal cancers.
Main Methods:
- Tumor specimens from 53 patients (31 stomach, 7 esophageal cancers) were utilized.
- Tumor fragments were implanted under the renal capsule of ddY mice (SRC assay).
- Chemotherapeutic agents were administered for 3 days, and tumor weight variations were measured.
Main Results:
- An 84.9% evaluability rate was achieved for the SRC assay.
- Tumor specimens showed a 26.7% response rate to chemotherapeutic agents in the assay.
- A 72.9% correlation rate was observed between SRC assay sensitivity and clinical responses.
- The assay demonstrated 100% accuracy in predicting clinical resistance.
Conclusions:
- The SRC assay is a viable method for predicting individual tumor sensitivity to chemotherapy.
- The assay shows significant potential for guiding personalized treatment decisions in upper gastro-intestinal oncology.
- The SRC assay's predictive accuracy for resistance is particularly noteworthy.